Patents Assigned to PHICO THERAPEUTICS
  • Anti-bacterial compositions comparing lytic modified bacteriophage engineered to infect and kill different target bacteria
    Patent number: 11732243
    Abstract: A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria; wherein the bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 22, 2023
    Assignee: PHICO THERAPEUTICS LTD
    Inventors: Heather Fairhead, Adam Wilkinson
  • Modified bacteriophage
    Patent number: 11559560
    Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: January 24, 2023
    Assignee: PHICO THERAPEUTICS LTD.
    Inventors: Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
  • Multiple host range bacteriophage with hybrid tail fibres
    Patent number: 11492601
    Abstract: Modified bacteriophage, uses thereof, and compositions containing the modified bacteriophage are described. The compositions are useful for human treatment and may treat various conditions, including bacterial infections.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: November 8, 2022
    Assignee: PHICO THERAPEUTICS LTD.
    Inventors: Heather Fairhead, Adam Wilkinson, Katy Pitts, Anne Barnard, Emmanuele Severi, Neil Anderson
  • Multiple host range bacteriophage with different tail fibres
    Patent number: 11236306
    Abstract: Modified bacteriophage and compositions containing the modified bacteriophage are described. Exemplary compositions are useful for human treatment and may treat various conditions, including bacterial infections.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: February 1, 2022
    Assignee: PHICO THERAPEUTICS LTD
    Inventors: Heather Fairhead, Adam Wilkinson, Emmanuele Severi, Neil Anderson, Katy Pitts, Anne Barnard
  • Modifying bacteriophage
    Patent number: 10953052
    Abstract: A method for modifying the genome of a lytic target phage, uses of the method and products thereof are described. Compositions comprising such phage are also described. The compositions may be formulated as a medicament, which are useful for human treatment and may treat various conditions, including bacterial infections.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: March 23, 2021
    Assignee: PHICO THERAPEUTICS LTD
    Inventors: Heather Fairhead, Adam Wilkinson, Anne Barnard, Emmanuele Severi, Neil Anderson, Katy Pitts
  • Modified bacteriophage
    Patent number: 10106784
    Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 23, 2018
    Assignee: PHICO THERAPEUTICS
    Inventors: Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
  • Modified bacteriophage including an alpha/beta small acid-soluble spore protein (SASP) gene
    Patent number: 9359596
    Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: June 7, 2016
    Assignee: PHICO THERAPEUTICS LTD.
    Inventors: Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
  • Modified Bacteriophage Including an Alpha/Beta Small Acid-Soluble Spore Protein (SASP) Gene
    Publication number: 20140242032
    Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 28, 2014
    Applicant: PHICO THERAPEUTICS LTD.
    Inventors: Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
  • Use of Polynucleotides Encoding Small Acid-Soluble Spore Protein for Inhibiting Bacterial Cell Growth and/or Treating Bacterial Infections
    Publication number: 20100209393
    Abstract: A polypeptide having ?/? type SASP activity, for use as a medicament.
    Type: Application
    Filed: November 3, 2009
    Publication date: August 19, 2010
    Applicant: PHICO THERAPEUTICS LTD.
    Inventor: Heather Marie Fairhead